Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$74.88 USD

74.88
686,225

+1.34 (1.82%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US

QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.

Globus Medical Sees Strong Rebound Despite Coronavirus Crisis

Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.

QIAGEN Launches Primer Panel for NGS of Coronavirus Genome

QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.

Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates

Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 163.64% and 49.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Aug 5: RMD, ABC & More

Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products in the second quarter.

Globus Medical (GMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical Faces Business Loss Amid Coronavirus Crisis

Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.

New Strong Sell Stocks for May 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of -27.50% and -4.65%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Globus Medical (GMED) Down 28.9% Since Last Earnings Report?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

Globus Medical Gains From International Spine Arm, Innovation

Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.

Globus Medical Stock Up on Solid '19 Preliminary Results

Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

Here's Why You Should Hold on to Globus Medical Stock for Now

Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.

Globus Medical Rides on New Product Menu, U.S. Spine Business

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Globus Medical Hits 52-Week High: What's Driving the Stock?

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

Why Is Globus Medical (GMED) Up 3.9% Since Last Earnings Report?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical's U.S. Spine Arm Grows, Product Launches Aid

Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.

Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

Globus Medical (GMED) Q3 Earnings Meet Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 0.00% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.